Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH. Can-Fite’s drugs have an excellent safety profile with experience in over 1,000 patients. Can-Fite’s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date.

CANF has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases. The company’s platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory and cancer cells where low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. The company's four current clinical trial programs target a combined market opportunity estimated at more than $80 billion, and a recent strategic agreement with Univo Pharmaceuticals provides additional upside from cannabinoid-based treatments targeting the same A3AR receptor. CANF has secured multiple corporate partnerships and out-licensing deals and has received an estimated $18 million to date in upfront and milestone payments. Multiple near-term milestones expected in second half 2019.

  • Advanced clinical stage drug development company with a compelling platform technology
    • All drugs are orally bioavailable with an excellent safety profile
    • CANF’s lead compound, CF101, is an oral drug that has been successfully tested in animal models and is currently in advanced stages of clinical development for Rheumatoid Arthritis (RA) and Psoriasis
    • CF102 is an oral drug currently being developed for the treatment of hepatocellular carcinoma (Primary Liver Cancer)
    • CF602 is a next generation compound with robust anti-inflammatory effects proven in a variety of autoimmune inflammatory and inflammatory animal models, and will be developed as a second-generation anti-inflammatory drug

  • Small molecule drug products in Phase II and Phase III clinical studies; covered by 13 patent families issued and pending
    • NAFLD / NASH Phase II data expected 2H19; $35B opportunity
    • Liver Cancer Phase III trial design expected to complete 2H19; $1.4B opportunity
    • Rheumatoid Arthritis Phase III trial ongoing; $35B opportunity
    • Psoriasis Phase III trial ongoing; $11.4B opportunity

close up of a cannabis plant held in hands wearing blue gloves

  • Developing cannabinoid-based treatments for cancer, inflammatory, autoimmune, and metabolic diseases
    • Collaborating on development through strategic partnership with Univo Pharmaceuticals
    • Developing assays for other pharma companies; additional potential revenue driver

  • Highly experienced management, clinical, and regulatory team

doctor and buissness man shaking hands

  • Successful corporate partnerships and licensing deals
    • Approximately $18 million upfront and milestone payments received to date
    • Partnerships with Kwang Dong (South Korea), Cipher (Canada), Chong Kun Dang (South Korea), Gebro Pharma (Europe), and China Medical System (Hong Kong)